Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis

Richard H Tuligenga

1INSERM U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Bât 15/16, 16 Avenue Paul Vaillant Courtois, 94807 Paris, Villejuif Cedex, France
2Université Paris Sud, UMRS 1018 Paris, Villejuif, France

Abstract

The aim of this meta-analysis was to compare the effect of intensive vs standard glycaemic control on cognitive decline in type 2 diabetic patients. A systematic search of PubMed and ALOIS was conducted from inception up to October 30, 2014. Randomised controlled trials (RCTs) of type 2 diabetic patients comparing the rate of change in cognitive function among participants assigned to intensive vs standard glycaemic control were included. An inverse-variance-weighted random effects model was used to calculate standardised mean differences (SMDs) and 95% CIs. A total of 24,297 patients from five RCTs were included in the meta-analysis. Follow-up ranged from 3.3 to 6.2 years. The result from the pooled analysis showed that intensive glycaemic control was not associated with a slower rate of cognitive decline in patients with type 2 diabetes, compared with standard glycaemic control (SMD = 0.02; 95% CI = –0.03 to 0.08) although there was some heterogeneity across individual studies (I² = 68%, P for heterogeneity = 0.01). There are few diabetes control trials including cognitive endpoints and a small number of trials comparing intensive and standard treatment strategies. Currently, intensive glycaemic control should not be recommended for prevention of cognitive decline in patients with type 2 diabetes because there is no evidence of its effectiveness. Moreover, the use of intensive diabetes treatment results in an increase of risk of hypoglycaemia, which is linked to a greater risk of poor cognition.

Key Words
- type 2 diabetes mellitus
- intensive glycaemic control
- cognitive decline
- meta-analysis
- randomised controlled trial

Introduction

Patients with type 2 diabetes mellitus show faster cognitive decline compared with healthy subjects (1). Numerous studies in patients with type 2 diabetes have dealt with the association between the level of glycaemic control and the subsequent rate of cognitive decline (2, 3, 4, 5, 6), but results are debated (7). Several studies (8, 9, 10, 11) have examined the effect of diabetes treatment on the risk of cognitive decline in type 2 diabetic patients and so far most findings have been inconclusive (12). Recent randomised controlled trials (RCTs) show that intensive glycaemic control does not have beneficial effects on the rate of cognitive decline (13, 14, 15, 16). The increased frequency of hypoglycaemia in patients treated intensively may partially explain the absence of beneficial effects (13, 14, 16). Hypoglycaemia can occur as a side effect of diabetes treatment and is more frequent in treatments that aim at intensive glycaemic control than in standard glycaemic control (17). A study demonstrates that
hypoglycaemia is a risk factor for poor cognition (18). In this study, hypoglycaemia was shown to increase the risk of dementia more than two decades later.

Intensive glycaemic control aims at achieving and maintaining glycaemia as close to normal as possible, regardless of the pharmacological therapy used (19). However, glycaemic target level varies across different studies with HbA1c target levels in the intensive treatment groups ranging between 6.0 and 7.0%. Standard glycaemic control is less rigid and allows higher HbA1c levels usually between 7.5 and 8.0 (20). The main arguments in favour of the attitude towards intensive treatment of type 2 diabetes are based on the results of the UK Prospective Diabetes Study (UKPDS). This study found that intensive glycaemic control is associated with a reduced risk of microvascular (21, 22) and some cardiovascular diseases (CVDs) (23, 24).

Three recent studies confirmed these beneficial effects, but suggested that intensive glycaemic control does not reduce the risk of CVD in older patients with long-standing type 2 diabetes (13, 25, 26). As type 2 diabetes affects cognitive function, intensive diabetes control may prevent the onset of microvascular disease in the brain, as well as cognitive decline (27). Thus, restoring a normoglycaemic state could logically mitigate the cognitive effects of type 2 diabetes. However, mixed findings are reported (10, 13, 14, 15, 16, 28, 29) about the effect of intensive glycaemic control when compared with standard glycaemic control on cognitive decline.

Although not all type 2 diabetes linked cognitive decline progresses to dementia (30), the risk of developing dementia is significantly increased (31). Persons with diabetes are 1.5 times more likely to develop Alzheimer’s disease and 2.5 times more likely to develop vascular dementia than those without diabetes (32). The presence of gradual cognitive decline over several years before the diagnosis of dementia is well established (33, 34, 35). Thus, slowing the rate of cognitive decline is especially important for preventing dementia among persons at risk such as diabetic patients, especially as no effective therapeutic treatment of dementia is currently available.

In view of the importance of maintaining cognitive function in type 2 diabetes mellitus and conflicting findings regarding the effect of intensive glycaemic control on subsequent cognitive decline (7), a meta-analysis of RCTs was conducted with the aim to determine whether intensive compared with standard glycaemic control was associated with a slower change in cognitive function over time in type 2 diabetic patients.

**Methods**

This meta-analysis was conducted in accordance with the PRISMA guidelines (36).

**Search strategy and selection criteria**

A systematic search of the literature up to October 30, 2014 was performed in the PubMed electronic database using the following terms with no restrictions: for the exposure, we used ‘intensive glycaemic control’ or ‘intensive glucose control’ or ‘diabetes treatment’ and, for the outcome, we used ‘cognition’ or ‘cognitive decline’ or ‘cognitive function’. We also searched ALOIS – the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register, where pharmacological interventions in type 2 diabetes patients were selected. Additional separate searches were run in the Cochrane Central Register of Controlled Trials (CENTRAL) and other clinical trial registers to ensure that the search was as comprehensive as possible or to identify unpublished studies. The references included in identified studies were checked for other potentially relevant studies.

Articles that met all the following inclusion criteria were sought and included: randomised, controlled trial study design; enrolment of patients with type 2 diabetes mellitus; comparing two strategies of glycaemic control (intensive and standard) and at least two measures of cognitive function over time.

**Data extraction and quality assessment**

Relevant data were extracted from each study. The extracted data included: number of participants, mean age of participants, duration of type 2 diabetes mellitus, persons with a history of CVD, mean of BMI, pre-specified HbA1c levels target in the intervention group, HbA1c level achieved, mean duration of follow-up, mean rate of cognitive decline in each group or mean difference of rate of cognitive decline.

Quality assessment for studies included in the meta-analysis was determined and internal validity was assessed based on Cochrane Collaboration Criteria (37) for three types of biases: random sequence generation and allocation concealment (selection bias), blinding of assessment of cognitive function (detection bias) and incomplete outcome data (attrition bias).

**Data extraction and statistical analysis**

The primary endpoint was the difference in cognitive decline in groups with intensive and standard glycaemic
and statistical methodology was overcome by calculating the standardised differences of the means (SMDs) and 95% CI for the $\beta$ coefficients.

For the meta-analysis, Review Manager (RevMan 5.3) was used. The generic inverse variance method (38) was used to group the trials. Each trial is given a weight that is equal to the inverse of the variance of the effect estimate. Thus, large trials that have smaller standard errors are given more weight than smaller trials, which have larger standard errors. This method minimises the imprecision of the pooled effect estimate. A random effect model was

---

**Figure 1**

Flowchart of study identification, inclusion and exclusion.

Records identified through PubMed ($n=588$)
ALOIS ($n=19$)

Additional records identified through other sources ($n=5$)

Records screened for relevance ($n=612$)

Articles excluded based on title and abstract or duplicate studies ($n=591$)

Full text articles assessed for eligibility ($n=21$)

Full text excluded with reason: not RCT ($n=3$), individuals with MCI or AD ($n=2$), placebo-controlled ($n=1$), reported only baseline results ($n=2$), or controls did not received standard treatment ($n=6$)

Articles appropriate for this meta-analysis ($n=7$)

Studies included in quantitative synthesis ($n=5$)

Two articles excluded for unclear methodology and for inadequate assessment of the outcome
used to allow for variability among the participants, the type of intervention, control group and outcome definitions. The $\chi^2$ test and $I^2$ statistics were calculated as a measure to evaluate statistical heterogeneity among studies (39). The test for overall effect ($z$ statistics with $P$ value) was provided. Sensitivity analyses were conducted based on the specified HbA1c target in the intervention group according to current recommendations; that is, trials with HbA1c target below 7% or those for which the HbA1c target was 7% or higher.

**Results**

The systematic search of PubMed/Medline and ALOIS database yielded abstracts for 607 publications. Additional searches identified five articles. After reading the titles and abstracts, 591 were excluded as clearly ineligible (mostly not RCT or participants with type 1 diabetes) or were duplicates. Copies of the full published version of each paper were obtained, which were then carefully assessed against inclusion/exclusion criteria. Additional studies were excluded subsequently for the following reasons: participants already suffering from Alzheimer’s disease or cognitive impairment, not controlled studies or not randomised studies, cognitive function assessed only at baseline, placebo-controlled study, or controls did not receive standard treatment of diabetes.

Seven studies that evaluated the effects of use of intensive diabetes treatment on cognitive decline in type 2 diabetic patients were identified (Fig. 1). Of these, two studies were excluded subsequently for the following reasons: the first study (10) of 40 diabetic patients was probably underpowered to detect expected adverse effects and did not provide power analysis to estimate the sample size unlike other selected studies. This study had also a short duration of 6 weeks. In the second study (28), cognitive function was assessed by the Cognitive Failure Questionnaire, which is a cognitive test that has been shown to have limitations for the study of cognitive aging and that is not considered to be a reliable test for measuring cognitive function (40, 41). Thus, five RCTs were considered for the meta-analysis. For one (13) of these, more information was requested from the authors in order to be able to use the data in the meta-analysis in another form than the one provided in the publication.

**Table 1** shows the characteristics extracted from the included trials. These trials included a total of 12 165 participants randomised in intensive groups and 12 132 randomised in standard groups, with sample sizes in individual studies ranging from 135 to 10 320 participants.
Baseline mean age of participants at randomisation across studies ranged from 59 to 70 years. The duration of type 2 diabetes mellitus at baseline ranged from 5.4 to 10.8 years, except for one study which included patients with screen-detected type 2 diabetes mellitus (15). Three trials selected participants with a higher risk of cardiovascular events (13, 14, 16). Another trial included elderly patients who were 70 years old on average at randomisation with a relatively well-controlled diabetes (29). In one of the five trials (13), cognition was not a primary outcome. Follow-up periods ranged from 3.3 to 6.2 years.

In four trials, patients receiving intensive treatment showed similar rates of cognitive decline to those assigned to standard treatment. Only one RCT showed that intensive therapy compared with standard therapy was associated with a slower rate of cognitive decline. Figure 2 shows the forest plot of the effect of intensive glycaemic control on the rate of cognitive decline compared with standard glycaemic control. There was no statistical difference between intensive and standard glycaemic control, and significant heterogeneity was found (SDM 0.02; 95% CI = -0.03 to 0.08; $I^2 = 68\%$, $P$ for heterogeneity = 0.01).

In sensitivity analysis, the effect of intensive glycaemic control in reducing cognitive decline was assessed based on HbA1c target in the intervention group at baseline. No difference was reported in two trials with HbA1c target below 7% in the intervention group and in three trials with HbA1c target of 7% or higher. Figure 3 shows pooled results of cognitive decline in patients with intensive HbA1c of <7% and Fig. 4 shows pooled results of cognitive decline in patients with intensive HbA1c of 7–8%.

The quality of studies included in the meta-analysis in terms of randomisation and report of losses to follow-up was generally high (Table 2). Four of the five studies reported the randomisation process, which was adequate in three trials. None of the five trials was double blinded. Follow-up was well documented in all studies.

**Discussion**

The results from this meta-analysis indicate that intensive glycaemic control was not associated with an increased or decreased cognitive decline compared with standard glycaemic control in patients with type 2 diabetes. To our knowledge, besides published commentaries (27), this study is the first to analyse clinical trial results on the association between intensive glycaemic control and cognitive decline using a meta-analytic approach.

Overall, there is no evidence of beneficial effects of intensive glycaemic control on cognitive decline. A beneficial effect was observed in only one trial targeting elderly persons with well-controlled type 2 diabetes (29). There are limitations to this study. The improvement in HbA1c was not reported, cognition was evaluated by a test

**Figure 2**
The effect of intensive vs standard glycaemic control on cognitive decline in type 2 diabetic patients.

**Figure 3**
Pooled results of cognitive decline in patients with intensive HbA1c of <7%.
designed for dementia screening (42, 43) and the effect size was small (β coefficient Z 0.03 and P Z 0.01). The results of this trial cannot be generalised because it included highly selected elderly patients (mean age at randomisation Z 70.6 years) who may have a survival benefit. Furthermore, this trial used two targets in the intervention group according to the profile of participants; the HbA1c target of ≤7% was fixed for everyone, except for participants at a high risk of hypoglycaemia for whom the target was of ≤8%. The remaining four trials included in the meta-analysis showed that the rate of cognitive decline was similar between intensive and standard glycaemic control groups. Pre-specified HbA1c target may not have any impact on the association between intensive glycaemic control and cognitive decline because there was no difference between trials with HbA1c target below current recommendations and trials with HbA1c target of 7% or higher. Some authors argue that participants randomised to the control group might be motivated by participation in a trial or might receive optimal diabetes care (14, 44). This may result in no large differences in healthcare between the intervention and standard treatment groups and may partly explain the lack of effect of the intervention. Note that none of the trials was double blinded. The duration of the interventions was < 10 years in all trials. Considering the importance of duration of diabetes on cognition (6, 45), those interventions may not be long enough to highlight the differences on a phenomenon as complex and multifactorial as cognition.

Intensive glycaemic control has been suggested as important in preventing or delaying microvascular complications of type 2 diabetes mellitus as a result of the UKPDS (23). Three recent trials, Action to Control Cardiovascular Risk in Diabetes (ACCORD) (25), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) (13), and Veteran Affairs Diabetes Trial (VADT) (26) confirmed these effects, but the effects on cardiovascular outcomes have been equivocal. These trials reported that intensive glycaemic control reduces microvascular complications, but does not reduce macrovascular complications in older patients with long-standing type 2 diabetes and high cardiovascular risk. As some complications of type 2 diabetes mellitus affect the brain, it is hoped that diabetes treatment may have benefits for cognition. However, the present meta-analysis showed a neutral effect of intensive glycaemic control on the rate of cognitive decline in patients with type 2 diabetes mellitus. It is increasingly clear that hypoglycaemia in intensively treated type 2 diabetic patients may contribute to cognitive decline and explain the absence of beneficial effect of intensive treatment (13, 14, 16). Hypoglycaemia is more common in intensive glycaemic control than in standard glycaemic control (17). In the ADVANCE trial, high frequency of severe hypoglycaemia was observed in patients with severe

### Table 2  Assessment of risk of bias of studies included in meta-analysis.

<table>
<thead>
<tr>
<th>Trial</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of assessment of cognitive function</th>
<th>Incomplete outcome data</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADVANCE</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>ACCORD MIND</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>ADDITION</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>IDEATEL</td>
<td>Unclear</td>
<td>High</td>
<td>Low</td>
<td>Unclear</td>
</tr>
<tr>
<td>ORIGIN</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>

Figure 4  
Pooled results of cognitive decline in patients with intensive HbA1c of 7–8%.
cognitive dysfunction (46). Results of the ACCORD MIND trial confirmed this finding, reporting an increase in hypoglycaemic events with use of intensive treatment (25), albeit a HbA1c target of 6.0% was used in this study. This trial also reported an increased mortality among intensively treated persons. Note that a HbA1c target level of 7% is recommended by current guidelines for management of type 2 diabetes (47, 48, 49). In the ORIGIN trial, intensive treatment based on insulin increased hypoglycaemia and modestly increased weight (50).

Hypoglycaemia remains a matter of concern for both clinicians and researchers particularly because the search for optimal glycaemic control to prevent complication of type 2 diabetes mellitus may be limited by the occurrence of hypoglycaemia. This may contribute to therapeutic inertia. There are few studies that have specifically examined the relationship between hypoglycaemia and cognition. A study of more than 1000 patients with type 2 diabetes aged between 60 and 75 years showed an association between self-reported severe hypoglycaemia and poor late-life cognitive abilities (51). Severe hypoglycaemia occurring between 55 and 65 years is a risk factor for incident dementia, as shown by the results from a diabetes registry. In this study, the risk for incident dementia was increased by 26% in diabetic patients who experienced one severe episode of hypoglycaemia, 80% for two hypoglycaemia events and 96% for three or more hypoglycaemia events (18). Inversely, cognitive deficits may also increase the risk of hypoglycaemic events. The Fremantle Diabetes Study showed that dementia was a risk factor for the occurrence of severe hypoglycaemia (52). In the ADVANCE trial, impaired cognitive function predicted severe hypoglycaemic events (46). This suggests a bidirectional relationship.

The major limitation of this meta-analysis was the small number of studies identified. There was a large heterogeneity in baseline characteristics across trials in terms of duration of type 2 diabetes mellitus, history of CVD and glycaemic target. Evidence for a specific anti-hyperglycaemic agent is lacking because the effects of different classes of antihyperglycaemic agents compared with each other were not reported in these trials.

In conclusion, this meta-analysis summarised the results of RCTs comparing the effect of intensive and standard glycaemic control on the rate of cognitive decline. The results suggest that intensive glycaemic control does not reduce the rate of cognitive decline in type 2 diabetic patients. Moreover, the use of intensive glycaemic control results in an increase in the risk of hypoglycaemia. Further treatment strategies to maintain cognitive function in type 2 diabetic patients with greater consideration of neurological consequences of hypoglycaemic events in the long term should be investigated.

Declaration of interest
The author declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This review did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
11 Ryan CM, Freed ML, Rood JA, Cobitz AR, Waterhouse BR & Strachan MW. Improving metabolic control leads to better working
28 Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). UK Prospective Diabetes Study Group. *Diabetes Care* 1999 **22** 1125–1136. (doi:10.2337/diacare.22.7.1125)  


51 Aung PP, Strachan MW, Frier BM, Butcher I, Deary IJ & Price JF. Edinburgh Type 2 Diabetes Study investigators, severe hypoglycaemia and late-life cognitive ability in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetic Medicine* 2012 **29** 328–336. (doi:10.1007/s00125-012-2308-x)


Received in final form 19 February 2015
Accepted 23 February 2015